CPC A61K 36/064 (2013.01) [A61K 9/28 (2013.01); A61K 9/4825 (2013.01); A61K 9/5042 (2013.01); A61K 31/327 (2013.01); A61K 35/742 (2013.01); A61K 35/748 (2013.01); A61K 38/44 (2013.01); A61P 31/04 (2018.01)] | 16 Claims |
1. An oral formulation in solid form for inhibiting intestinal anaerobic bacteria comprising a plurality of individually coated granules contained within a capsule, wherein each coated granule comprises:
an oxygen prodrug,
wherein the oxygen prodrug is encased within a controlled release coating;
a catalyst,
wherein the catalyst controls the rate of conversion of the oxygen prodrug to oxygen at a target site in an intestine of a subject,
a semipermeable coating surrounding the catalyst and the oxygen prodrug, wherein the semipermeable coating has a pore size that prevents at least a majority of the catalyst from diffusing out of the semipermeable coating and prevents at least one intestinal digestive enzyme from diffusing into the semipermeable coating, and
an enteric coating;
wherein when orally administered to a subject and upon reaching the target site in the intestine of the subject, the catalyst catalyzes conversion of the oxygen prodrug to generate oxygen and create an aerobic environment at the target site in the intestine of the subject sufficient to inhibit growth or toxicity of a population of anaerobic bacteria in the intestine.
|